OSA-related arousal burden could raise the dose needed for any sleep-mediated neuroprotective effect, perhaps toward 100 mg rather than 50 mg. This is the least supported development hypothesis because it depends on a long causal chain from OSA physiology to biomarker benefit in dementia and is heavily confounded by standard OSA care and endotype heterogeneity.
Radar Chart — 10 Dimensions
Score Comparison Bars
Mechanistic
0.34
Evidence
0.21
Novelty
0.46
Feasibility
0.51
Impact
0.30
Druggability
0.50
Safety
0.47
Competition
0.36
Data
0.35
Reproducible
0.24
KG Connect
0.50
Score Breakdown
Dimension
Patients with OSA or high noct
Mechanistic
0.340
Evidence
0.210
Novelty
0.460
Feasibility
0.510
Impact
0.300
Druggability
0.500
Safety
0.470
Competition
0.360
Data
0.350
Reproducible
0.240
KG Connect
0.500
Evidence
Patients with OSA or high nocturnal arousal burden may requi